These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
364 related items for PubMed ID: 17591025
1. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Qi X, Xiong S, Yang H, Miller M, Delaney WE. Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025 [Abstract] [Full Text] [Related]
2. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). Osiowy C, Villeneuve JP, Heathcote EJ, Giles E, Borlang J. J Clin Microbiol; 2006 Jun; 44(6):1994-7. PubMed ID: 16757589 [Abstract] [Full Text] [Related]
3. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen. Svarovskaia ES, Curtis M, Zhu Y, Borroto-Esoda K, Miller MD, Berg T, Lavocat F, Zoulim F, Kitrinos KM. J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548 [Abstract] [Full Text] [Related]
4. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants. Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM. Antivir Ther; 2012 Feb; 17(4):701-9. PubMed ID: 22358132 [Abstract] [Full Text] [Related]
5. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898 [Abstract] [Full Text] [Related]
7. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients. Liu Y, Liu W, Li X, Xu Z, Wang X, Li C, Chen L, Xin S, Xu D. Antivir Ther; 2014 Jun; 19(6):551-8. PubMed ID: 24710668 [Abstract] [Full Text] [Related]
14. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouée-Durantel S, Villeneuve JP, Trépo C, Zoulim F. Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463 [Abstract] [Full Text] [Related]
15. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil. Liu Y, Li X, Xin S, Xu Z, Chen R, Yang J, Liu L, Wong VW, Yang D, Chan HL, Xu D. J Viral Hepat; 2015 Mar; 22(3):328-34. PubMed ID: 25132017 [Abstract] [Full Text] [Related]
17. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Chen CH, Wang JH, Lee CM, Hung CH, Hu TH, Wang JC, Lu SN, Changchien CS. Antivir Ther; 2006 Mar; 11(6):771-8. PubMed ID: 17310821 [Abstract] [Full Text] [Related]
18. [Resistance to adefovir in patients with chronic hepatitis B]. Ryu SH, Chung YH. Korean J Hepatol; 2006 Dec; 12(4):484-92. PubMed ID: 17237626 [Abstract] [Full Text] [Related]
19. rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B. Liu LJ, Wang JH, Du SC, Tian JH, Yang RF, Wei L. J Viral Hepat; 2010 Mar; 17 Suppl 1():66-72. PubMed ID: 20586936 [Abstract] [Full Text] [Related]